News

Search For News


TRY IT NOW

Sign up online today & collaborate

or click here to find out more

Search results for {{term}}

1. Ergomed plc Provides Update on Co-Development Partnerships.

Ergomed plc Provides Update on Co-Development Partnerships.16/12/2015Ergomed plc, (LSE: ERGO) a profitable UK-based company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, provides an update on its current co-development partnerships. Ergomed’s four active partnerships have studies in late stage development with the potential to deliver significant Phase II and Phase III news flow with two studies scheduled to report resul


2. Malin Announces Investment in Gene Therapy Company Poseida Therapeutic

Malin Announces Investment in Gene Therapy Company Poseida Therapeutics, Inc.16/12/2015Malin Corporation plc. ("Malin"), an Irish-based global life sciences company, today announced that it has agreed to invest up to $30 million in Poseida Therapeutics, Inc. ("Poseida"), to acquire a shareholding of up to approximately 31%.Poseida is a US-based, privately-held human therapeutics company focused on the development of novel therapies using its ground-breaking proprietary genome engineering technol


3. Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and

Bayer and CRISPR Therapeutics AG Join Forces to Discover, Develop and Commercialize Potential Cures for Serious Genetic Diseases.21/12/2015The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from


4. Magdalen College Acquires 100% of The Oxford Science Park.

Magdalen College Acquires 100% of The Oxford Science Park.04/01/2016Oxford, UK – Magdalen College has completed the acquisition of the 50% stake in The Oxford Science Park joint venture held by M&G Real Estate, to take 100% control of the management and future development of the Park.  The consideration was £18.1m in cash.The Oxford Science Park was established in 1991 as a 50/50 joint venture to deliver high-quality commercial offices and laboratories for science and technol


5. Shire to Combine with Baxalta, Creating the Global Leader in Rare Dise

Shire to Combine with Baxalta, Creating the Global Leader in Rare Diseases11/01/2016Shire plc (LSE: SHP, NASDAQ: SHPG) and Baxalta Incorporated (NYSE: BXLT) today announced that the boards of directors of both companies have reached an agreement under which Shire will combine with Baxalta. Under the agreement, Baxalta shareholders will receive $18.00 in cash and 0.1482 Shire ADS per Baxalta share. Based on Shire’s closing ADS price on January 8, 2016, this implies a total current value of



Page 9 of 30 ( 148 results in total )
© Catalyst Innovation Portal 2019